Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Jane Lim

MOHS-Micrographic Surgery Evansville, IN Medical Doctor

NPI 1699778050 CMS profile 212381

421 Chestnut St, Evansville, IN 47713

Open in the dashboard

General payments

$4,188

237 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Jane Lim of Evansville, IN is reported in the CMS Open Payments database as having received $4,188 across 237 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $902 57
2021 General $1,428 77
2020 General $628 41
2019 General $1,229 62

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jane Lim
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to Jane Lim were reported at $0. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year Jane Lim MOHS-Micrographic Surgery median Middle half National median
2019 $1,229 $316 $106–$785 $163
2020 $628 $162 $68–$412 $114
2021 $1,428 $243 $87–$654 $132
2022 $902 $300 $102–$887 $149
2023 $0 $364 $125–$1,010 $160
2024 $0 $445 $142–$1,108 $164
2025 $0 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. AbbVie, Inc. $1,014 68 payments
  2. Sun Pharmaceutical Industries Inc. $479 30 payments
  3. Novartis Pharmaceuticals Corporation $445 30 payments
  4. Genzyme Corporation $390 10 payments
  5. Ortho Dermatologics, a division of Bausch Health US, LLC $210 14 payments
  6. Janssen Biotech, Inc. $201 12 payments
  7. Amgen Inc. $165 9 payments
  8. Lilly USA, LLC $160 10 payments
  9. Dermira, Inc. $133 3 payments
  10. Celgene Corporation $116 1 payment
  11. Other $876 50 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $4,188 237 payments
Products named General payments · program years 2019–2022
  1. SKYRIZI $691 45 payments
  2. HUMIRA $617 42 payments
  3. ILUMYA $375 19 payments
  4. COSENTYX Immunology $309 18 payments
  5. RINVOQ $196 12 payments
  6. LIBTAYO Oncology $190 5 payments
  7. TALTZ $144 9 payments
  8. DUPIXENT $134 7 payments
  9. LIBTAYO Oncology $124 1 payment
  10. COSENTYX Dermatology $120 11 payments
  11. Other $2,146 122 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

237 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record